Exo develops a handheld ultrasound device together with Exo Works, a point-of-care workflow platform that streamlines exam review, documentation and billing in under one minute. The device combines artificial intelligence, medical imaging and silicon technology to enable use in settings from cardiology to lung scans and at-home monitoring. Exo says the device will cost around the price of a laptop, aiming to make ultrasound more widely accessible. The company is focused immediately on commercializing the device, building out its informatics platform (currently being piloted across the U.S.), and ramping production and its sales force. Exo has raised over $320 million in total funding since its 2015 founding, including a $40 million raise in 2020. The company plans to bring the handheld device to market after securing U.S. FDA approval and is based in Redwood City, California. Exo is developing a handheld ultrasound device built on patented Piezoelectric Micromachined Ultrasound Transducer (pMUT) technology intended to deliver industry-leading image quality, affordability and portability. The device is paired with cloud-based workflow software and data apps designed to improve interoperability, documentation and clinician workflow in emergency and critical care settings. Exo will use its Series B+ funding to finish product development and bring its data and workflow apps to market. The company says its technology is intended to image denser body compositions and provide powerful diagnostic capabilities for frontline physicians. Exo highlights a team with experience from Apple, GE, Google, Johnson & Johnson, Maxim, Medtronic and Siemens and envisions a multi-functional platform that could converge diagnostics and therapeutics. Financially, the Series B+ follows an August 2019 Series B that raised $35 million and brings Exo’s total funding to nearly $100 million.

Total raised

$260M

Funding rounds

2

Latest round

Series C

Latest activity

Jul 2021